Search clinical trials for: FluMist® Quadrivalent

Total 14071 results

Stanford University
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Genetic and Environmental Factors in the Response to Influenza Vaccination (SLVP028)

Healthy | Influenza

United States
MedImmune LLC
AstraZeneca

Completed

Evaluate the Shedding and Immunogencity of Different Formulations of FluMist in Children 24 to <48 Months of Age (FluMist)

Healthy | Influenza

United States
University of Colorado, Denver
MedImmune LLC

Completed

Shedding, Immunogenicity and Safety of Quadrivalent Live Intranasal Influenza Vaccine (QLAIV) in HIV-infected Children and Young Adults (QLAIV)

Human Immunodeficiency Virus (HIV)

United States
Stanford University
National Institute of Allergy and Infectious Diseases (NIAID); National Institutes...

Completed

The Effects of Attenuated Versus Inactivated Flu Vaccine in Twin Sets (FLU-TW)

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5407 in Adult Participants18 Years of Age and Older

Influenza Immunization

Puerto Rico, United States
National Institute of Allergy and Infectious Diseases...

Withdrawn

Safety and Effectiveness of a Seasonal Live Attenuated Influenza Vaccine in a Human Challenge Model of Infection With Wild-type (wt) Influenza A/California/2009 (H1N1)-Like Virus

Influenza, Human

United States
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5413 in Adult Participants18 Years of Age and Older

Influenza Immunization

Australia, United States, Puerto Rico
Sanofi Pasteur, a Sanofi Company

Recruiting

A Study to Investigate the Safety and Immunogenicity of the Quadrivalent Influenza mRNA Vaccines in Adults Aged 18 Years and Above

Influenza Immunization

United States, Puerto Rico
Stanford University
National Institute of Allergy and Infectious Diseases (NIAID)

Terminated

Adaptive Immune Responses and Repertoire in Influenza Vaccination and Infection (SLVP031)

Influenza

United States
Stanford University
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Innate and Acquired Immunity to Influenza Infection and Immunization (SLVP029)

Influenza

United States
Stanford University
National Institute of Allergy and Infectious Diseases (NIAID)

Terminated

Tissue-specific Responses to Influenza Immunization and Their Relation to Blood Biomarkers (SLVP032)

Influenza
Stanford University
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

The Human Mucosal Immune Responses to Influenza Virus (SLVP026)

Influenza
Stanford University
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Protective Mechanisms Against a Pandemic Respiratory Virus (SLVP024)

Influenza
Stanford University
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

The Role of CD4+ Memory Phenotype, Memory, and Effector T Cells in Vaccination and Infection (SLVP030)

Healthy | Influenza

United States
Stanford University
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) - Year 1, 2009

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5410 in Adult Participants 18 Years of Age and Older

Influenza Immunization

United States, Puerto Rico
University of Alabama at Birmingham

Active, not recruiting

Live Attenuated Influenza Vaccine as a Nasal Model for Influenza Infection

Influenza

United States
MedImmune LLC

Completed

A Clinical Study to Assess the Safety of a New Influenza Vaccine

Healthy

United States
Sanofi Pasteur, a Sanofi Company

Completed

Substudy 01 - Safety and Immunogenicity of One Monovalent Modified mRNA Vaccine Encoding Influenza Hemagglutinin With LNP, in Adult Participants Aged 18 to 49 Years and 60 Years and Above

Influenza Immunization

Australia, United Kingdom
Duke University
Johns Hopkins University; Centers for Disease Control and Prevention

Completed

Simultaneous RZV and aIIV4 Vaccination

Quality of Life | Pain | Adverse Drug Event | Injection Site Reaction

United States
McGill University Health Centre/Research Institute...
Canadian Cystic Fibrosis Foundation; PHAC/CIHR Influenza Research Network; Ministere...

Unknown

LAIV (Flumist®) Administration in CF Patients

Cystic Fibrosis

Canada
GlaxoSmithKline

Completed

Study to Evaluate Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine GSK2282512A When Administered to Children From 6 to 35 Months of Age

Influenza

United States
GlaxoSmithKline

Completed

A Study of Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine FLU-Q-QIV in Adults Aged 18 Years and Older

Influenza

Canada
GlaxoSmithKline

Completed

Study to Evaluate the Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Quadrivalent Influenza Vaccine (GSK2282512A) Compared to Fluzone® Quadrivalent in Children 6 to 35 Months of Age

Influenza

United States, Mexico
MedImmune LLC

Completed

A Study to Evaluate the Immunogenicity of Quadrivalent LAIV in Adults 18 to 49 Years of Age (MI-CP185)

Healthy or Stable Underlying Chronic Medical Condition

United States
Medicago

Completed

Immunogenicity of a Quadrivalent Virus-Like Particles (VLP) Influenza Vaccine in Healthy Adults

RNA Virus Infections | Virus Diseases | Respiratory Tract Infections | Respiratory Tract Diseases

United States, Canada
Sanofi

Completed

Safety Surveillance of VaxigripTetra® and Efluelda® Influenza Vaccines in Europe During the Influenza Season 2023/24

Influenza Immunization (Healthy Volunteers)

Finland, Germany
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of the 2015-2016 Formulation of Fluzone® Quadrivalent (Influenza Vaccine) Among Healthy Children

Influenza

United States
Stanford University
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) Year 4, 2012

Influenza
Sanofi Pasteur, a Sanofi Company

Completed

Safety Surveillance of VaxigripTetra® and Efluelda® Influenza Vaccines in Europe During the Influenza Season 2022/23

Influenza (Healthy Volunteers)

Germany, Finland
Sanofi Pasteur, a Sanofi Company

Completed

Safety Surveillance of VaxigripTetra® and Efluelda® Influenza Vaccines in Europe During the Influenza Season 2021/22

Influenza (Healthy Volunteers)

Germany, Finland
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Quadrivalent, Influenza Vaccine

Influenza

United States
MedImmune LLC

Completed

Trial to Assess the Shedding,Immunogenicity, and Safety of FluMist Administered to Healthy Individuals 5-49 Years of Age

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study of Fluzone® Quadrivalent, Fluzone® Intradermal Quadrivalent, and Fluzone® High-Dose, Influenza Vaccines in Adults

Influenza

United States
Partha Basu
All India Institute of Medical Sciences, New Delhi; Tata Memorial Centre; Deutsches... and other collaborators

Active, not recruiting

Trial of Two Versus Three Doses of Human Papillomavirus (HPV) Vaccine in India

Cervical Cancer | Cervical Precancerous Lesions

India
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Quadrivalent Influenza Virus Vaccine

Influenza

United States
Medicago

Completed

Immunogenicity, Safety, and Tolerability of a Plant-Derived Quadrivalent VLP Influenza Vaccine in Elderly Adults

RNA Virus Infections | Virus Diseases | Respiratory Tract Infections | Respiratory Tract Diseases

United States, Canada
Yale University
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and other collaborators

Recruiting

Intradermal Influenza Vaccination

Vaccine Reaction

United States
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of Fluzone® Quadrivalent, Southern Hemisphere 2015 Formulation (Intramuscular Route)

Influenza

Philippines
Sanofi Pasteur, a Sanofi Company

Terminated

Study With Quadrivalent Recombinant Influenza Vaccine (RIV4) Compared With Egg-Based Quadrivalent Influenza Vaccine (IIV4) in Participants Aged 3 to 8 Years

Influenza Immunization

United States, Denmark, Poland, Spain
ModernaTX, Inc.

Active, not recruiting

A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Adults

Influenza

United States
Medicago

Completed

Efficacy of a Plant-derived Quadrivalent Virus-like Particle (VLP) Vaccine in the Elderly

RNA Virus Infections | Virus Diseases | Respiratory Tract Infections | Respiratory Tract Diseases

United States, Canada, Finland, Germany, Thailand
MedImmune LLC

Completed

A Study to Evaluate the Safety of a Monovalent Vaccine in Healthy Adults

Healthy

United States
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of Fluzone® Quadrivalent Vaccine Administered to Healthy Children

Influenza

United States, United Kingdom
MedImmune LLC

Completed

A Study to Evaluate the Immunogenicity of Quadrivalent Live Attenuated Influenza Vaccine (LAIV) in Children (LAIV)

Healthy or Stable Chronic Illness

United States
GlaxoSmithKline

Completed

A Study to Evaluate the Efficacy of GSK Biologicals' Influenza Vaccine in Children

Influenza

Thailand, Bangladesh, Dominican Republic, Honduras, Lebanon, Panama, Philippines, Turkey
ModernaTX, Inc.

Active, not recruiting

A Study of mRNA-1345 Vaccine Targeting Respiratory Syncytial Virus (RSV) in Adults ≥50 Years of Age (RSVictory)

Respiratory Syncytial Virus

United States
Sanofi Pasteur, a Sanofi Company

Completed

Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively

Healthy Volunteers | Influenza Immunization

United States
Sanofi Pasteur, a Sanofi Company

Completed

Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2020-2021 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively

Healthy Volunteers | Influenza Immunization

United States
MedImmune LLC

Completed

Trial to Demonstrate Equivalent Immunogenicity of CAIV-T and FLUMIST in Healthy Participants

Healthy

United States

3

Subscribe